Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Tumor inhibiting medicine composition and purpose thereof

A technology of anti-tumor drugs and compositions, applied in the field of compositions containing arctigenin and pyrimidine nucleotide synthesis inhibitors, and anti-tumor drug compositions, which can solve the problems of long drug effect time, high treatment cost, and large side effects, etc. question

Active Publication Date: 2012-02-01
SHANDONG NEWTIME PHARMA
View PDF2 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] In order to solve the shortcomings of existing tumor therapeutic drugs in clinical application, especially the defects of large side effects and high treatment cost in most current tumor therapeutic drugs, the present invention provides a drug with long drug effect time, low price and less side effects combination

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tumor inhibiting medicine composition and purpose thereof
  • Tumor inhibiting medicine composition and purpose thereof
  • Tumor inhibiting medicine composition and purpose thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0062] The preparation of embodiment 1 arctigenin and capecitabine tablet

[0063] The tablet formulation of table 7 arctigenin and capecitabine composition

[0064]

[0065] Preparation process: Pass arctigenin and capecitabine through 80-mesh sieve respectively, weigh according to the prescription amount, mix evenly, then mix evenly with hydroxypropyl cyclodextrin in equal increments, pass through 60-mesh sieve, and then mix with Mix the rest of the excipients in the prescribed amount evenly, measure the content of the semi-finished product, calculate the weight of the tablet, and press the tablet.

Embodiment 2

[0066] Embodiment 2 Preparation of Arctigenin Gemcitabine Sustained Release Tablets

[0067] Table 8 Sustained-release tablet formulations of arctigenin and gemcitabine compositions

[0068]

[0069] Preparation process: Weigh arctigenin, gemcitabine, carbomer, and hydroxypropyl cellulose in prescription quantities and mix evenly. Take another appropriate amount of 8% starch slurry solution, add it to the mixed powder, mix evenly to make a soft material, pass through a 16-mesh sieve to granulate, and dry below 60°C. After the drying is completed, use an 18-mesh sieve to carry out granulation, sieve out the fine powder in the dry granules, mix with the sieved magnesium stearate, and then mix with the dry granules evenly, and press into tablets to obtain the product.

Embodiment 3

[0070] Embodiment 3 Preparation of arctigenin and tegafur microemulsion composition preparation

[0071] Table 9 arctigenin and tegafur microemulsion composition preparation 1

[0072]

[0073] Preparation process: Weigh 30 mg caprylic acid glyceride and 50 mg emulsifier OP, add to 20 mg propylene glycol, and mix well to obtain a suspension solution. Accurately weigh 25 mg of arctigenin and 0.25 mg of tegafur, add them to the suspension solution, and ultrasonically dissolve the arctigenin and tegafur to obtain the microemulsion concentrate of the arctigenin and tegafur composition. The microemulsion concentrate obtained above is diluted with water according to the weight ratio of 1:10-20 to a clear solution to obtain the microemulsion.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a solid tumor inhibiting medicine composition composed of arctigenin and a pyrimidine nucleotide synthetic inhibitor, wherein a weight ratio of the components is 1:0.001-1000, and preferably 1:0.01-100. Pharmacodynamic tests show that, the medicine composition provides substantial synergetic effects in the treatments of solid tumors, especially leukemia. The medicine composition provided by the invention has advantages of wide tumor inhibiting spectrum, small side effect, low treatment cost, and good prospect in clinical application.

Description

technical field [0001] The invention relates to an anti-tumor pharmaceutical composition and its use, in particular to a composition containing arctigenin and pyrimidine nucleotide synthesis inhibitors and its use against solid tumors, belonging to the technical field of medicines. Background technique [0002] Tumor cells grow faster than most normal cells and need to synthesize more nucleotides as precursors for DNA and RNA synthesis, so they are more sensitive to nucleotide synthesis inhibitors than normal cells. A range of chemotherapeutic agents work by inhibiting one or more enzymes of the nucleotide synthesis pathway. [0003] Nucleotide is the basic unit of ribonucleic acid and deoxyribonucleic acid, and is the precursor of nucleic acid synthesis in vivo. Nucleotides are distributed along with nucleic acids in the nucleus and cytoplasm of various organs, tissues, and cells in organisms, and as components of nucleic acids, they participate in basic life activities su...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/365A61K31/7068A61K31/513A61K31/7072A61K31/519A61K31/401A61K31/655A61P35/00A61K31/27A61K31/198
Inventor 赵志全
Owner SHANDONG NEWTIME PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com